Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 12/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.40 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033771 | 0.89 | IL2 (0.56) | IL2KDM4ENPC1ALDH1A1MAPK1 | |
| SCHEMBL5029603 | 0.88 | IL2 (0.53) | IL2KDM4ENPC1ALDH1A1MAPK1 | |
| SCHEMBL2894140 | 0.88 | IL2 (0.53) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL5030853 | 0.86 | IL2 (0.50) | IL2KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL5027346 | 0.84 | IL2 (0.49) | IL2KDM4ENPC1ALDH1A1MAPK1 | |
| SCHEMBL13640659 | 0.84 | IL2 (0.51) | IL2KDM4ENPC1ALDH1A1MAPK1 | |
| SCHEMBL2813178 | 0.83 | IL2 (0.64) | IL2KDM4ENPC1ALDH1A1MAPK1 | |
| SCHEMBL14360751 | 0.83 | IL2 (0.51) | IL2KDM4ENPC1ALDH1A1MAPK1 | |
| SCHEMBL2891235 | 0.82 | IL2 (0.51) | IL2KDM4ENPC1ALDH1A1MAPK1 | |
| SCHEMBL5030860 | 0.81 | IL2 (0.48) | IL2KDM4ENPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | claimed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | claimed |
| US-8435996-B2 | Heterocycle-aryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-07 | — | — | US | claimed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | claimed |
| EP-2184994-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | claimed |
| WO-2009017818-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2184994-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009017818-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885KDM4E 2266/4885NPC1 199/4885 |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | IL2 6/4885KDM4E 1502/4885NPC1 1781/4885 |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885KDM4E 2266/4885NPC1 199/4885 |
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, NOD1 | IL2 23/4885KDM4E 895/4885NPC1 640/4885 |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | IL2 6/4885KDM4E 1502/4885NPC1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.